WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR ), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera's Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.
"Leigh has distinguished herself as an expert in developing world-class organizations in a wide variety of settings, and I'm thrilled to welcome her to Kymera's Board of Directors," said Nello Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera Therapeutics. "Given our aspirations to evolve Kymera into a fully-integrated, global biopharmaceutical company, her extensive background across critical business functions will provide our team with an invaluable resource as we scale our operations and advance as a best-in-class degrader medicines company."
"A pioneer in the field of targeted protein degradation, Kymera has rapidly transformed into a clinical stage company, and is now dosing patients in multiple clinical programs in immunology and oncology," said Ms. Morgan. "I am excited to join the team and help them continue their evolution and achieve ...
Full story available on Benzinga.com